EP3541414 - CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS [Right-click to bookmark this link] | Status | The patent has been granted Status updated on 26.07.2024 Database last updated on 02.09.2024 | |
Former | Grant of patent is intended Status updated on 03.04.2024 | ||
Former | Examination is in progress Status updated on 22.03.2024 | ||
Former | Grant of patent is intended Status updated on 27.11.2023 | ||
Former | Examination is in progress Status updated on 25.08.2023 | ||
Former | Request for examination was made Status updated on 23.08.2019 | ||
Former | The international publication has been made Status updated on 25.05.2018 | Most recent event Tooltip | 26.07.2024 | (Expected) grant | published on 28.08.2024 [2024/35] | Applicant(s) | For all designated states OBI Pharma, Inc. Room W1907, 19F, 3 Yuanqu Street Nangang District Taipei City, 115 / TW | [2024/35] |
Former [2019/39] | For all designated states OBI Pharma, Inc. Room W1907, 19F, 3 Yuanqu Street Nangang District Taipei City, 115 / TW | Inventor(s) | 01 /
CHANG, Michael Nientse 19F., N0. 3, Yuanqu St. Nangang Dist. Tapei City 115 / TW | 02 /
LAI, Jiann-Shuin c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | 03 /
LI, Wan-Fen c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | 04 /
CHEN, I-Ju c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | 05 /
TSAI, Yi-Chien c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | 06 /
CHEN, Kai-Chuan c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | [2019/45] |
Former [2019/39] | 01 /
CHANG, Michael Nientse 6020 Cornerstone Ct. W. San Diego, California 92121 - 3730 / US | ||
02 /
LAI, Jiann-Shuin c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | |||
03 /
LI, Wan-Fen c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | |||
04 /
CHEN, I-Ju c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | |||
05 /
TSAI, Yi-Chien c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | |||
06 /
CHEN, Kai-Chuan c/o OBI Pharma, Inc. Room W1907, 19F, No.3, Yuanqu Street Nangang District Taipei City, 115 / TW | Representative(s) | Schlee, Alexander Richard Schlee IP International Maximilianstraße 33 80539 München / DE | [2024/35] |
Former [2019/39] | HGF Limited 4th Floor Merchant Exchange 17-19 Whitworth Street West Manchester M1 5WG / GB | Application number, filing date | 17871220.4 | 21.11.2017 | [2019/39] | WO2017US62886 | Priority number, date | US201662424851P | 21.11.2016 Original published format: US 201662424851 P | [2019/39] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018094414 | Date: | 24.05.2018 | Language: | EN | [2018/21] | Type: | A1 Application with search report | No.: | EP3541414 | Date: | 25.09.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 24.05.2018 takes the place of the publication of the European patent application. | [2019/39] | Type: | B1 Patent specification | No.: | EP3541414 | Date: | 28.08.2024 | Language: | EN | [2024/35] | Search report(s) | International search report - published on: | KR | 24.05.2018 | (Supplementary) European search report - dispatched on: | EP | 14.10.2020 | Classification | IPC: | A61K39/00, A61K47/68, A61K49/16, A61P35/04, C07K16/18, C07K16/44, A61K39/395, A61P35/00 | [2020/33] | CPC: |
A61K47/6855 (EP,US);
A61K39/0011 (KR);
A61K39/39558 (EP,US);
A61K45/06 (US);
A61K47/68031 (EP,US);
A61K47/6811 (US);
A61K47/6817 (EP,US);
A61K47/6843 (US);
A61K47/6851 (KR);
A61K47/6857 (EP,US);
A61K47/6859 (US);
A61K47/6863 (EP,US);
A61K49/0058 (US);
A61K49/16 (KR,US);
A61K51/1018 (US);
A61K51/1051 (US);
A61K51/1054 (US);
A61K51/1057 (US);
A61K51/1063 (US);
A61P31/00 (KR);
A61P35/00 (EP,KR,US);
A61P35/04 (EP,US);
A61P37/06 (KR);
C07K16/18 (EP,US);
C07K16/3076 (US);
C07K16/44 (EP,US);
C08B37/0006 (US);
G01N33/57492 (US);
A61K2039/505 (EP,US);
A61K2039/54 (EP,US);
A61K2039/545 (EP,US);
A61K2039/6056 (KR);
C07K2317/24 (US);
| C-Set: |
A61K39/39558, A61K2300/00 (EP,US)
|
Former IPC [2019/39] | A61K39/00, A61K47/68, A61K49/16 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/39]
![]() | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | KONJUGIERTE BIOLOGISCHE MOLEKÜLE, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERFAHREN | [2019/39] | English: | CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | [2019/39] | French: | MOLÉCULES BIOLOGIQUES CONJUGUÉES, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS | [2019/39] | Entry into regional phase | 20.05.2019 | National basic fee paid | 20.05.2019 | Search fee paid | 20.05.2019 | Designation fee(s) paid | 20.05.2019 | Examination fee paid | Examination procedure | 20.05.2019 | Examination requested [2019/39] | 10.06.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time | 20.08.2021 | Amendment by applicant (claims and/or description) | 28.08.2023 | Despatch of a communication from the examining division (Time limit: M02) | 27.10.2023 | Reply to a communication from the examining division | 28.11.2023 | Communication of intention to grant the patent | 19.03.2024 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 19.03.2024 | Fee for grant paid | 19.03.2024 | Fee for publishing/printing paid | 04.04.2024 | Communication of intention to grant the patent | 21.07.2024 | Fee for grant paid | 21.07.2024 | Fee for publishing/printing paid | 21.07.2024 | Receipt of the translation of the claim(s) | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 20.08.2021 | Request for further processing filed | 20.08.2021 | Full payment received (date of receipt of payment) Request granted | 01.09.2021 | Decision despatched | Fees paid | Renewal fee | 28.02.2020 | Renewal fee patent year 03 | 13.11.2020 | Renewal fee patent year 04 | 21.10.2021 | Renewal fee patent year 05 | 13.10.2022 | Renewal fee patent year 06 | 29.09.2023 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 30.11.2019 | 03   M06   Fee paid on   28.02.2020 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2016118961 (ACADEMIA SINICA, et al); | [XP]WO2017172990 (OBI PHARMA INC, et al); | [E]WO2018023121 (OBI PHARMA INC, et al); | [E]WO2018232349 (DEV CT BIOTECHNOLOGY, et al); | International search | [X]US2012294859 (GOLETZ STEFFEN [DE], et al); | [X]US2012328646 (WONG CHI-HUEY [TW], et al); | [X]WO2015157629 (YU CHENG-DER TONY, et al); | [XA]WO2016118961 (ACADEMIA SINICA, et al); | [PX]US2017283488 (YU CHENG-DER TONY [TW], et al); | by applicant | US4816567 | US4975278 | WO9704801 | WO03043583 | US2004018194 | WO2004032828 | WO2005007197 | US7595292 | WO2016118961 | US2017101462 | WO2017062792 | WO2075US95292 |